Key Highlights
- Michael A. Ibara, Pharm.D., appointed as Chief Strategy Officer.
- Leads global strategic initiatives and AI technology launch.
- Focus on enhancing clinical research and patient value.
- Experienced in biopharmaceutical industry and data operations.
Source: Business Wire
Notable Quotes
- “I look forward to working with the team to develop AI-driven solutions to improve clinical research and deliver innovative solutions to help patients get better value from participating in clinical trials.” — Michael A. Ibara,
Chief Strategy Officer at Avallano
- “Michael’s extensive experience in the biopharmaceutical industry and his innovative approach to data and clinical operations make him the perfect fit for Avallano.” — Paul Della Maggiora, Co-Founder and CEO at Avallano
SoHC's Take
The appointment of Dr. Michael A. Ibara as Chief Strategy Officer marks a significant step for Avallano as it continues to push the boundaries of clinical research through advanced AI technologies. With Dr. Ibara’s proven track record in leveraging electronic health records for clinical trial feasibilities and operations, Avallano is poised to enhance patient engagement and streamline trial processes. His leadership is expected to drive innovation and compliance, addressing critical challenges in clinical research and ensuring that patients and sponsors derive maximum value from the company’s cutting-edge solutions.
